183 related articles for article (PubMed ID: 31222450)
1. Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis.
Wu N; Fu F; Chen L; Lin Y; Yang P; Wang C
Clin Transl Oncol; 2020 Apr; 22(4):474-485. PubMed ID: 31222450
[TBL] [Abstract][Full Text] [Related]
2. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
Campbell EJ; Tesson M; Doogan F; Mohammed ZMA; Mallon E; Edwards J
Br J Cancer; 2016 Oct; 115(8):967-973. PubMed ID: 27657341
[TBL] [Abstract][Full Text] [Related]
3. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
4. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
[TBL] [Abstract][Full Text] [Related]
5. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
6. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers.
Raghav KP; Hernandez-Aya LF; Lei X; Chavez-Macgregor M; Meric-Bernstam F; Buchholz TA; Sahin A; Do KA; Hortobagyi GN; Gonzalez-Angulo AM
Cancer; 2012 Mar; 118(6):1498-506. PubMed ID: 21837669
[TBL] [Abstract][Full Text] [Related]
7. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
9. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
Precht LM; Lowe KA; Atwood M; Beatty JD
Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
[TBL] [Abstract][Full Text] [Related]
12. Hormone receptor status and mitotic activity as risk factors for recurrence and death in female breast carcinoma.
Aaltomaa S; Lipponen P; Eskelinen M; Kosma VM; Marin S; Alhava E; Syrjänen K
Anticancer Res; 1991; 11(5):1701-6. PubMed ID: 1768039
[TBL] [Abstract][Full Text] [Related]
13. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
[TBL] [Abstract][Full Text] [Related]
14. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
[TBL] [Abstract][Full Text] [Related]
16. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
Bal O; Yalcintas Arslan U; Durnali A; Uyetrk U; Demirci A; Tastekin D; Ekinci A; Esbah O; Turker I; Uysal Sonmez O; Oksuzoglu B
J BUON; 2015; 20(1):28-34. PubMed ID: 25778292
[TBL] [Abstract][Full Text] [Related]
17. Hormone Receptor Expression on Endocrine Therapy in Patients with Breast Cancer: A Meta-Analysis.
Zhong Y; Ding B; Qian L; Wu W; Wen Y
Am Surg; 2022 Jan; 88(1):48-57. PubMed ID: 33382340
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
19. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
20. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]